Artificial Intelligence (AI) is leading technological advancements in the pharmaceutical sector, poised to transform pre-clinical drug discovery by reducing costs by up to 40% and creating a market valued at up to $50 billion in the next decade. This transformative period is upon us, and the AI in Drug Discovery conference offers a unique opportunity to hear directly from experts and gain strategies to enhance your operations.

Scheduled for October 2024 in the United States, the AI in Drug Discovery Conference comes after a successful event in March 2024 in the UK. Since then, the industry has achieved a groundbreaking milestone: the first wholly AI-discovered and designed drug is now in Phase 2 clinical trials.

Time: 8:00 AM – 4:30 PM

Venue details: Courtyard Boston Downtown, 275 Tremont Street, Boston, Massachusetts, 02116, United States

Price:
AI in Drug Discovery (EARLY BIRD DISCOUNT UNTIL 09/06/24): USD 2399.00

Speakers: DR BINO JOHN – Director, Computational Biology, Cancer Immunology and Immune Modulation, Boehringer Ingelheim, DR DMITRIY PODOLSKIY – Associate Director, Astellas Pharma, DR PETRINA KAMYA – President, Insilico Medicine Canada Inc., and Global Head of AI Platforms, VP, Insilico Medicine, DR STEPHEN MACKINNON – VP of Digital Chemistry, Recursion Pharmaceuticals, DR VISHNU SRESHT – Director, Precision Labs, Genentech